English
简体中文
Total: £ 56.28
Published Date: 2025-06-19 | Pages: 93 | Tables: 93 | Medical Care
The global market for Hirudin-based Drugs was valued at US$ 4200 million in the year 2024 and is projected to reach a revised size of US$ 5134 million by 2031, growing at a CAGR of 3.0% during the forecast period.
Hirudin is a natural anticoagulant protein initially extracted from leeches, known for its powerful blood-thinning properties. It works by directly binding to thrombin, inhibiting its activity, and thus effectively preventing blood coagulation. Over time, the production of hirudin has transitioned from natural extraction to recombinant DNA technology, significantly improving production efficiency, safety, and product consistency. Common hirudin-based products include Lepirudin (Refludan) and Desirudin (Iprivask), which are primarily used in the treatment and prevention of thrombotic diseases such as deep vein thrombosis (DVT), pulmonary embolism (PE), and thrombus-related cardiovascular conditions. Hirudin products are particularly suitable for patients who cannot use traditional anticoagulants, such as those with heparin-induced thrombocytopenia (HIT). These products have a longer half-life and can be used during surgeries for anticoagulation therapy. Additionally, they are frequently applied in intensive care units and dialysis treatments.
The demand for hirudin-based drugs is growing, primarily driven by the increasing incidence of thrombotic diseases, the aging population, and the rising need for safer and more effective anticoagulants. With technological advancements, the production costs of hirudin-based medicines are gradually decreasing, making them more affordable. Moreover, the application of these drugs in specific patient populations is expanding, further increasing their market potential.
The market for hirudin-based drugs is experiencing rapid growth, driven by several key factors. First, the incidence of thrombotic diseases, especially cardiovascular diseases, deep vein thrombosis, and pulmonary embolism, is steadily rising, providing a solid foundation for the demand for hirudin-based products. As the global population ages, the need for treatment of thrombotic diseases will continue to increase, positively impacting the market for hirudin drugs. Secondly, hirudin has gained increasing recognition as an alternative to traditional anticoagulants. For patients who cannot tolerate heparin or warfarin, the efficacy and safety of hirudin make it a crucial alternative option.
However, the market for hirudin-based drugs faces some challenges. Firstly, the production process of hirudin is complex and relatively costly, which could limit its adoption in some developing countries. Secondly, there are still certain side effects and safety concerns associated with hirudin, especially in elderly and multi-morbid patients. Balancing efficacy and side effects remains a key challenge in the market. Additionally, with the presence of established anticoagulants like heparin and warfarin, hirudin-based drugs need to offer significant advantages in terms of safety, efficacy, and cost to capture a larger market share.
In terms of market concentration, the hirudin-based drug market is currently dominated by a few large companies, such as Boehringer Ingelheim and Sanofi, leading to a relatively concentrated competitive landscape. However, with advances in biotechnology, more small and medium-sized enterprises are entering the market, increasing diversification and competition. Downstream demand is expected to grow, particularly in Asia and emerging markets, as healthcare conditions improve and awareness of thrombotic disease prevention rises.
Technologically, research and development in hirudin-based drugs are focused on enhancing molecular stability and prolonging half-life. The application of new recombinant technologies has not only reduced production costs but also improved the consistency and quality of the drugs. With these technological advancements, the scope of hirudin-based drugs continues to expand, and the market prospects are promising.
This report aims to provide a comprehensive presentation of the global market for Hirudin-based Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hirudin-based Drugs.
The Hirudin-based Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hirudin-based Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hirudin-based Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Teva Pharmaceuticals
Pfizer, Inc
Pentapharm
DUOPUTAI
Abbott
Keyken
Minapharm
Salubris Bio
Hoechst AG
Ciba-Geigy
Boehringer Ingelheim
Sanofi
Xellia Pharmaceuticals
Haplogen Pharmaceuticals
Shenzhen Kangtai Biological
Dong-A ST
Segment by Type
Natural Hirudin
Recombinant Hirudin
Segment by Application
Thrombosis Disease
Tumor Disease
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hirudin-based Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hirudin-based Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Natural Hirudin
1.2.3 Recombinant Hirudin
1.3 Market by Application
1.3.1 Global Hirudin-based Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Thrombosis Disease
1.3.3 Tumor Disease
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hirudin-based Drugs Market Perspective (2020-2031)
2.2 Global Hirudin-based Drugs Growth Trends by Region
2.2.1 Global Hirudin-based Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Hirudin-based Drugs Historic Market Size by Region (2020-2025)
2.2.3 Hirudin-based Drugs Forecasted Market Size by Region (2026-2031)
2.3 Hirudin-based Drugs Market Dynamics
2.3.1 Hirudin-based Drugs Industry Trends
2.3.2 Hirudin-based Drugs Market Drivers
2.3.3 Hirudin-based Drugs Market Challenges
2.3.4 Hirudin-based Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hirudin-based Drugs Players by Revenue
3.1.1 Global Top Hirudin-based Drugs Players by Revenue (2020-2025)
3.1.2 Global Hirudin-based Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Top Hirudin-based Drugs Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Hirudin-based Drugs Revenue
3.4 Global Hirudin-based Drugs Market Concentration Ratio
3.4.1 Global Hirudin-based Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hirudin-based Drugs Revenue in 2024
3.5 Global Key Players of Hirudin-based Drugs Head office and Area Served
3.6 Global Key Players of Hirudin-based Drugs, Product and Application
3.7 Global Key Players of Hirudin-based Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Hirudin-based Drugs Breakdown Data by Type
4.1 Global Hirudin-based Drugs Historic Market Size by Type (2020-2025)
4.2 Global Hirudin-based Drugs Forecasted Market Size by Type (2026-2031)
5 Hirudin-based Drugs Breakdown Data by Application
5.1 Global Hirudin-based Drugs Historic Market Size by Application (2020-2025)
5.2 Global Hirudin-based Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Hirudin-based Drugs Market Size (2020-2031)
6.2 North America Hirudin-based Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Hirudin-based Drugs Market Size by Country (2020-2025)
6.4 North America Hirudin-based Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hirudin-based Drugs Market Size (2020-2031)
7.2 Europe Hirudin-based Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Hirudin-based Drugs Market Size by Country (2020-2025)
7.4 Europe Hirudin-based Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Hirudin-based Drugs Market Size (2020-2031)
8.2 Asia-Pacific Hirudin-based Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Hirudin-based Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Hirudin-based Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Hirudin-based Drugs Market Size (2020-2031)
9.2 Latin America Hirudin-based Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Hirudin-based Drugs Market Size by Country (2020-2025)
9.4 Latin America Hirudin-based Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hirudin-based Drugs Market Size (2020-2031)
10.2 Middle East & Africa Hirudin-based Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Hirudin-based Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Hirudin-based Drugs Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Hirudin-based Drugs Introduction
11.1.4 Novartis Revenue in Hirudin-based Drugs Business (2020-2025)
11.1.5 Novartis Recent Development
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Company Details
11.2.2 Teva Pharmaceuticals Business Overview
11.2.3 Teva Pharmaceuticals Hirudin-based Drugs Introduction
11.2.4 Teva Pharmaceuticals Revenue in Hirudin-based Drugs Business (2020-2025)
11.2.5 Teva Pharmaceuticals Recent Development
11.3 Pfizer, Inc
11.3.1 Pfizer, Inc Company Details
11.3.2 Pfizer, Inc Business Overview
11.3.3 Pfizer, Inc Hirudin-based Drugs Introduction
11.3.4 Pfizer, Inc Revenue in Hirudin-based Drugs Business (2020-2025)
11.3.5 Pfizer, Inc Recent Development
11.4 Pentapharm
11.4.1 Pentapharm Company Details
11.4.2 Pentapharm Business Overview
11.4.3 Pentapharm Hirudin-based Drugs Introduction
11.4.4 Pentapharm Revenue in Hirudin-based Drugs Business (2020-2025)
11.4.5 Pentapharm Recent Development
11.5 DUOPUTAI
11.5.1 DUOPUTAI Company Details
11.5.2 DUOPUTAI Business Overview
11.5.3 DUOPUTAI Hirudin-based Drugs Introduction
11.5.4 DUOPUTAI Revenue in Hirudin-based Drugs Business (2020-2025)
11.5.5 DUOPUTAI Recent Development
11.6 Abbott
11.6.1 Abbott Company Details
11.6.2 Abbott Business Overview
11.6.3 Abbott Hirudin-based Drugs Introduction
11.6.4 Abbott Revenue in Hirudin-based Drugs Business (2020-2025)
11.6.5 Abbott Recent Development
11.7 Keyken
11.7.1 Keyken Company Details
11.7.2 Keyken Business Overview
11.7.3 Keyken Hirudin-based Drugs Introduction
11.7.4 Keyken Revenue in Hirudin-based Drugs Business (2020-2025)
11.7.5 Keyken Recent Development
11.8 Minapharm
11.8.1 Minapharm Company Details
11.8.2 Minapharm Business Overview
11.8.3 Minapharm Hirudin-based Drugs Introduction
11.8.4 Minapharm Revenue in Hirudin-based Drugs Business (2020-2025)
11.8.5 Minapharm Recent Development
11.9 Salubris Bio
11.9.1 Salubris Bio Company Details
11.9.2 Salubris Bio Business Overview
11.9.3 Salubris Bio Hirudin-based Drugs Introduction
11.9.4 Salubris Bio Revenue in Hirudin-based Drugs Business (2020-2025)
11.9.5 Salubris Bio Recent Development
11.10 Hoechst AG
11.10.1 Hoechst AG Company Details
11.10.2 Hoechst AG Business Overview
11.10.3 Hoechst AG Hirudin-based Drugs Introduction
11.10.4 Hoechst AG Revenue in Hirudin-based Drugs Business (2020-2025)
11.10.5 Hoechst AG Recent Development
11.11 Ciba-Geigy
11.11.1 Ciba-Geigy Company Details
11.11.2 Ciba-Geigy Business Overview
11.11.3 Ciba-Geigy Hirudin-based Drugs Introduction
11.11.4 Ciba-Geigy Revenue in Hirudin-based Drugs Business (2020-2025)
11.11.5 Ciba-Geigy Recent Development
11.12 Boehringer Ingelheim
11.12.1 Boehringer Ingelheim Company Details
11.12.2 Boehringer Ingelheim Business Overview
11.12.3 Boehringer Ingelheim Hirudin-based Drugs Introduction
11.12.4 Boehringer Ingelheim Revenue in Hirudin-based Drugs Business (2020-2025)
11.12.5 Boehringer Ingelheim Recent Development
11.13 Sanofi
11.13.1 Sanofi Company Details
11.13.2 Sanofi Business Overview
11.13.3 Sanofi Hirudin-based Drugs Introduction
11.13.4 Sanofi Revenue in Hirudin-based Drugs Business (2020-2025)
11.13.5 Sanofi Recent Development
11.14 Xellia Pharmaceuticals
11.14.1 Xellia Pharmaceuticals Company Details
11.14.2 Xellia Pharmaceuticals Business Overview
11.14.3 Xellia Pharmaceuticals Hirudin-based Drugs Introduction
11.14.4 Xellia Pharmaceuticals Revenue in Hirudin-based Drugs Business (2020-2025)
11.14.5 Xellia Pharmaceuticals Recent Development
11.15 Haplogen Pharmaceuticals
11.15.1 Haplogen Pharmaceuticals Company Details
11.15.2 Haplogen Pharmaceuticals Business Overview
11.15.3 Haplogen Pharmaceuticals Hirudin-based Drugs Introduction
11.15.4 Haplogen Pharmaceuticals Revenue in Hirudin-based Drugs Business (2020-2025)
11.15.5 Haplogen Pharmaceuticals Recent Development
11.16 Shenzhen Kangtai Biological
11.16.1 Shenzhen Kangtai Biological Company Details
11.16.2 Shenzhen Kangtai Biological Business Overview
11.16.3 Shenzhen Kangtai Biological Hirudin-based Drugs Introduction
11.16.4 Shenzhen Kangtai Biological Revenue in Hirudin-based Drugs Business (2020-2025)
11.16.5 Shenzhen Kangtai Biological Recent Development
11.17 Dong-A ST
11.17.1 Dong-A ST Company Details
11.17.2 Dong-A ST Business Overview
11.17.3 Dong-A ST Hirudin-based Drugs Introduction
11.17.4 Dong-A ST Revenue in Hirudin-based Drugs Business (2020-2025)
11.17.5 Dong-A ST Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Hirudin-based Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Natural Hirudin
Table 3. Key Players of Recombinant Hirudin
Table 4. Global Hirudin-based Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Hirudin-based Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Hirudin-based Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Hirudin-based Drugs Market Share by Region (2020-2025)
Table 8. Global Hirudin-based Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Hirudin-based Drugs Market Share by Region (2026-2031)
Table 10. Hirudin-based Drugs Market Trends
Table 11. Hirudin-based Drugs Market Drivers
Table 12. Hirudin-based Drugs Market Challenges
Table 13. Hirudin-based Drugs Market Restraints
Table 14. Global Hirudin-based Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Hirudin-based Drugs Market Share by Players (2020-2025)
Table 16. Global Top Hirudin-based Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hirudin-based Drugs as of 2024)
Table 17. Ranking of Global Top Hirudin-based Drugs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Hirudin-based Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Hirudin-based Drugs, Headquarters and Area Served
Table 20. Global Key Players of Hirudin-based Drugs, Product and Application
Table 21. Global Key Players of Hirudin-based Drugs, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Hirudin-based Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Hirudin-based Drugs Revenue Market Share by Type (2020-2025)
Table 25. Global Hirudin-based Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Hirudin-based Drugs Revenue Market Share by Type (2026-2031)
Table 27. Global Hirudin-based Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Hirudin-based Drugs Revenue Market Share by Application (2020-2025)
Table 29. Global Hirudin-based Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Hirudin-based Drugs Revenue Market Share by Application (2026-2031)
Table 31. North America Hirudin-based Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Hirudin-based Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Hirudin-based Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Hirudin-based Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Hirudin-based Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Hirudin-based Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Hirudin-based Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Hirudin-based Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Hirudin-based Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Hirudin-based Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Hirudin-based Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Hirudin-based Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Hirudin-based Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Hirudin-based Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Hirudin-based Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Novartis Company Details
Table 47. Novartis Business Overview
Table 48. Novartis Hirudin-based Drugs Product
Table 49. Novartis Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 50. Novartis Recent Development
Table 51. Teva Pharmaceuticals Company Details
Table 52. Teva Pharmaceuticals Business Overview
Table 53. Teva Pharmaceuticals Hirudin-based Drugs Product
Table 54. Teva Pharmaceuticals Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 55. Teva Pharmaceuticals Recent Development
Table 56. Pfizer, Inc Company Details
Table 57. Pfizer, Inc Business Overview
Table 58. Pfizer, Inc Hirudin-based Drugs Product
Table 59. Pfizer, Inc Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 60. Pfizer, Inc Recent Development
Table 61. Pentapharm Company Details
Table 62. Pentapharm Business Overview
Table 63. Pentapharm Hirudin-based Drugs Product
Table 64. Pentapharm Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 65. Pentapharm Recent Development
Table 66. DUOPUTAI Company Details
Table 67. DUOPUTAI Business Overview
Table 68. DUOPUTAI Hirudin-based Drugs Product
Table 69. DUOPUTAI Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 70. DUOPUTAI Recent Development
Table 71. Abbott Company Details
Table 72. Abbott Business Overview
Table 73. Abbott Hirudin-based Drugs Product
Table 74. Abbott Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 75. Abbott Recent Development
Table 76. Keyken Company Details
Table 77. Keyken Business Overview
Table 78. Keyken Hirudin-based Drugs Product
Table 79. Keyken Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 80. Keyken Recent Development
Table 81. Minapharm Company Details
Table 82. Minapharm Business Overview
Table 83. Minapharm Hirudin-based Drugs Product
Table 84. Minapharm Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 85. Minapharm Recent Development
Table 86. Salubris Bio Company Details
Table 87. Salubris Bio Business Overview
Table 88. Salubris Bio Hirudin-based Drugs Product
Table 89. Salubris Bio Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 90. Salubris Bio Recent Development
Table 91. Hoechst AG Company Details
Table 92. Hoechst AG Business Overview
Table 93. Hoechst AG Hirudin-based Drugs Product
Table 94. Hoechst AG Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 95. Hoechst AG Recent Development
Table 96. Ciba-Geigy Company Details
Table 97. Ciba-Geigy Business Overview
Table 98. Ciba-Geigy Hirudin-based Drugs Product
Table 99. Ciba-Geigy Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 100. Ciba-Geigy Recent Development
Table 101. Boehringer Ingelheim Company Details
Table 102. Boehringer Ingelheim Business Overview
Table 103. Boehringer Ingelheim Hirudin-based Drugs Product
Table 104. Boehringer Ingelheim Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 105. Boehringer Ingelheim Recent Development
Table 106. Sanofi Company Details
Table 107. Sanofi Business Overview
Table 108. Sanofi Hirudin-based Drugs Product
Table 109. Sanofi Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 110. Sanofi Recent Development
Table 111. Xellia Pharmaceuticals Company Details
Table 112. Xellia Pharmaceuticals Business Overview
Table 113. Xellia Pharmaceuticals Hirudin-based Drugs Product
Table 114. Xellia Pharmaceuticals Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 115. Xellia Pharmaceuticals Recent Development
Table 116. Haplogen Pharmaceuticals Company Details
Table 117. Haplogen Pharmaceuticals Business Overview
Table 118. Haplogen Pharmaceuticals Hirudin-based Drugs Product
Table 119. Haplogen Pharmaceuticals Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 120. Haplogen Pharmaceuticals Recent Development
Table 121. Shenzhen Kangtai Biological Company Details
Table 122. Shenzhen Kangtai Biological Business Overview
Table 123. Shenzhen Kangtai Biological Hirudin-based Drugs Product
Table 124. Shenzhen Kangtai Biological Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 125. Shenzhen Kangtai Biological Recent Development
Table 126. Dong-A ST Company Details
Table 127. Dong-A ST Business Overview
Table 128. Dong-A ST Hirudin-based Drugs Product
Table 129. Dong-A ST Revenue in Hirudin-based Drugs Business (2020-2025) & (US$ Million)
Table 130. Dong-A ST Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
Table 134. Authors List of This Report
List of Figures
Figure 1. Hirudin-based Drugs Picture
Figure 2. Global Hirudin-based Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Hirudin-based Drugs Market Share by Type: 2024 VS 2031
Figure 4. Natural Hirudin Features
Figure 5. Recombinant Hirudin Features
Figure 6. Global Hirudin-based Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Hirudin-based Drugs Market Share by Application: 2024 VS 2031
Figure 8. Thrombosis Disease Case Studies
Figure 9. Tumor Disease Case Studies
Figure 10. Others Case Studies
Figure 11. Hirudin-based Drugs Report Years Considered
Figure 12. Global Hirudin-based Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Hirudin-based Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Hirudin-based Drugs Market Share by Region: 2024 VS 2031
Figure 15. Global Hirudin-based Drugs Market Share by Players in 2024
Figure 16. Global Hirudin-based Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 17. The Top 10 and 5 Players Market Share by Hirudin-based Drugs Revenue in 2024
Figure 18. North America Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Hirudin-based Drugs Market Share by Country (2020-2031)
Figure 20. United States Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Hirudin-based Drugs Market Share by Country (2020-2031)
Figure 24. Germany Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Ireland Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Hirudin-based Drugs Market Share by Region (2020-2031)
Figure 32. China Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia & New Zealand Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Hirudin-based Drugs Market Share by Country (2020-2031)
Figure 40. Mexico Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Hirudin-based Drugs Market Share by Country (2020-2031)
Figure 44. Israel Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Hirudin-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Novartis Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 48. Teva Pharmaceuticals Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 49. Pfizer, Inc Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 50. Pentapharm Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 51. DUOPUTAI Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 52. Abbott Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 53. Keyken Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 54. Minapharm Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 55. Salubris Bio Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 56. Hoechst AG Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 57. Ciba-Geigy Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 58. Boehringer Ingelheim Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 59. Sanofi Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 60. Xellia Pharmaceuticals Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 61. Haplogen Pharmaceuticals Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 62. Shenzhen Kangtai Biological Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 63. Dong-A ST Revenue Growth Rate in Hirudin-based Drugs Business (2020-2025)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
